Last reviewed · How we verify
Placebo/ Duration of Treatment: 156 weeks — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo/ Duration of Treatment: 156 weeks (Placebo/ Duration of Treatment: 156 weeks) — Merck Sharp & Dohme LLC. Placebo is an inert substance with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo/ Duration of Treatment: 156 weeks TARGET | Placebo/ Duration of Treatment: 156 weeks | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo/ Duration of Treatment: 156 weeks CI watch — RSS
- Placebo/ Duration of Treatment: 156 weeks CI watch — Atom
- Placebo/ Duration of Treatment: 156 weeks CI watch — JSON
- Placebo/ Duration of Treatment: 156 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Placebo/ Duration of Treatment: 156 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-duration-of-treatment-156-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab